Key result
EVOQUE TTVR shows low paravalvular leak rates, though real-world outcomes vary by prosthesis size.
Why the study?
How does prosthesis size affect paravalvular leak and clinical outcomes after EVOQUE transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation?
How does prosthesis size affect paravalvular leak and clinical outcomes after EVOQUE transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation?
This study aims to provide real-world data on paravalvular leak and clinical outcomes stratified by prosthesis size after EVOQUE transcatheter tricuspid valve replacement.
The EVOQUE transcatheter tricuspid valve replacement (TTVR) system (Edwards Lifesciences) has demonstrated excellent results among patients with severe tricuspid regurgitation in pivotal trials; however, real-world data on paravalvular leak (PVL) stratified by prosthesis size remain limited.
No takes yet. Share an insight, caveat, or question.
Radaideh et al. (2026) studied this question. EVOQUE transcatheter tricuspid valve replacement has demonstrated excellent results in pivotal trials, though real-world data on paravalvular leak stratified by prosthesis size remain limited.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: